ArticleNucleic acids research2003
Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway.
Article in Nucleic acids research, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Recent Advances and Prospects of Nucleic Acid Therapeutics for Anti-Cancer Therapy.Molecules (Basel, Switzerland) · 2024Review
- Structural Modifications of siRNA Improve Its Performance In Vivo.International journal of molecular sciences · 2023Review
- Genome-wide identification and validation of tomato-encoded sRNA as the cross-species antifungal factors targeting the virulence genes ofFrontiers in plant science · 2023Article
- Optimization in Chemical Modification of Single-Stranded siRNA Encapsulated by Neutral Cytidinyl/Cationic Lipids.Frontiers in chemistry · 2022Article
- Foliar Delivery of siRNA Particles for Treating Viral Infections in Agricultural Grapevines.Advanced functional materials · 2021Article
- Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA.Molecular therapy. Nucleic acids · 2017Article
- Nanoparticle-based targeted therapeutics in head-and-neck cancer.International journal of medical sciences · 2015Review
- RNA/aTNA chimeras: RNAi effects and nucleases resistance of single and double stranded RNAs.Molecules (Basel, Switzerland) · 2014Article
- Argonaute-dependent small RNAs derived from single-stranded, non-structured precursors.Frontiers in genetics · 2014Review
- Self-duplexing CUG repeats selectively inhibit mutant huntingtin expression.Nucleic acids research · 2013Article
- ss-siRNAs allele selectively inhibit ataxin-3 expression: multiple mechanisms for an alternative gene silencing strategy.Nucleic acids research · 2013Article
- RNA interference-mediated targeting of DKK1 gene expression in Ishikawa endometrial carcinoma cells causes increased tumor cell invasion and migration.Oncology letters · 2013Article
- Transcriptional silencing by single-stranded RNAs targeting a noncoding RNA that overlaps a gene promoter.ACS chemical biology · 2013Article
- Design of siRNA Therapeutics from the Molecular Scale.Pharmaceuticals (Basel, Switzerland) · 2013Article
- CTR1 silencing inhibits angiogenesis by limiting copper entry into endothelial cells.PloS one · 2013Article
- RNAi joins the "Singles Club".Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Article
- mRNA knockdown by single strand RNA is improved by chemical modifications.Nucleic acids research · 2012Article
- Competition between small RNAs: a quantitative view.Biophysical journal · 2012Article
- Strand antagonism in RNAi: an explanation of differences in potency between intracellularly expressed siRNA and shRNA.Nucleic acids research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA interference (RNAi), mediated by either long double-stranded RNA (dsRNA) or short interfering RNA (siRNA), has become a routine tool for transient knockdown of gene expression in a wide range of organisms. The antisense strand of the siRNA duplex (antisense siRNA) was recently shown to have substantial mRNA depleting activity of its own. Here, targeting human Tissue Factor mRNA in HaCaT cells, we perform a systematic comparison of the activity of antisense siRNA and double-strand siRNA, and find almost identical target position effects, appearance of mRNA cleavage fragments and tolerance for mutational and chemical backbone modifications. These observations, together with the demonstration that excess inactive double-strand siRNA blocks antisense siRNA activity, i.e. shows sequence-independent competition, indicate that the two types of effector molecules share the same RNAi pathway. Interest ingly, both FITC-tagged and 3'-deoxy antisense siRNA display severely limited activity, despite having practically wild-type activity in a siRNA duplex. Finally, we find that maximum depletion of target mRNA expression occurs significantly faster with antisense siRNA than with double-strand siRNA, suggesting that the former enters the RNAi pathway at a later stage than double-strand siRNA, thereby requiring less time to exert its activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.